Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opus Genetics Inc (IRD)

Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

Biotech stocks are not for the faint of heart, as companies in the clinical stage push risk to the extreme. With key clinical data still to come, huge financial burn, and valuation almost entirely dependent on trial outcomes, these companies only offer massive upside if everything goes as planned. Here are two of the riskiest biotech stocks investors are betting on.

Opus Genetics (IRD) has emerged as one of the boldest and riskiest bets investors are making right now. Valued at $1.4 billion, Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent...

Fundamentals

See More
  • Market Capitalization, $K 137,928
  • Shares Outstanding, K 68,964
  • Annual Sales, $ 10,990 K
  • Annual Income, $ -57,530 K
  • EBIT $ -65 M
  • EBITDA $ -65 M
  • 60-Month Beta 0.42
  • Price/Sales 12.42
  • Price/Cash Flow N/A
  • Price/Book 19.88

Options Overview Details

View History
  • Implied Volatility 214.80% (+36.21%)
  • Historical Volatility 66.50%
  • IV Percentile 26%
  • IV Rank 18.21%
  • IV High 1,036.10% on 03/17/25
  • IV Low 31.89% on 09/16/25
  • Expected Move (DTE 27) 0.94 (46.75%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 312
  • Volume Avg (30-Day) 94
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 4,825
  • Open Int (30-Day) 4,607
  • Expected Range 1.07 to 2.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate -0.06
  • Low Estimate -0.15
  • Prior Year -1.27
  • Growth Rate Est. (year over year) +92.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.86 +7.53%
on 11/21/25
2.59 -22.80%
on 12/10/25
+0.14 (+7.53%)
since 11/19/25
3-Month
1.50 +33.33%
on 09/30/25
2.59 -22.80%
on 12/10/25
+0.48 (+31.58%)
since 09/19/25
52-Week
0.65 +207.69%
on 04/10/25
2.59 -22.80%
on 12/10/25
+1.01 (+102.61%)
since 12/19/24

Most Recent Stories

More News
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

These biotech bets are only for investors who can stomach volatility.

EYPT : 17.43 (+2.17%)
IRD : 2.00 (+1.01%)
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 2.00 (+1.01%)
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 2.00 (+1.01%)
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies...

IRD : 2.00 (+1.01%)
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited...

IRD : 2.00 (+1.01%)
Opus Genetics to Participate in Upcoming Investment Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene...

IRD : 2.00 (+1.01%)
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE...

IRD : 2.00 (+1.01%)
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision - - Successful FDA RMAT meeting provides the potential...

IRD : 2.00 (+1.01%)
Opus Genetics Announces $23 Million Registered Direct Offering

- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov....

IRD : 2.00 (+1.01%)
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for planned...

IRD : 2.00 (+1.01%)

Business Summary

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills,...

See More

Key Turning Points

3rd Resistance Point 2.14
2nd Resistance Point 2.08
1st Resistance Point 2.04
Last Price 2.00
1st Support Level 1.94
2nd Support Level 1.88
3rd Support Level 1.85

See More

52-Week High 2.59
Last Price 2.00
Fibonacci 61.8% 1.85
Fibonacci 50% 1.62
Fibonacci 38.2% 1.39
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar